NCT06080659Recruiting
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 22 Sept 2023
- Start date
- 6 Nov 2023
- Primary completion date
- Nov 2026
- Lead sponsor
- Rennes University Hospital
- Diseases
- Alzheimer disease, Parkinson disease
- NCT number
- NCT06080659
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 6 Nov 2023 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cochlear implants ;
Other illness
- Dementia according to McKhann criteria (McKhann et al., 2011)
- Sensory deficit interfering with experimental tests
- Healthy volunteers only
- \- Cognitive impairment (MoCA score \< 26)
Other
- All participants (healthy volunteers and patients)
- Contraindications to MRI :
- Abdominal circumference + upper limbs sticking to the body \> 200 cm;
- Implantable pacemaker or defibrillator;
- Neurosurgical clips;
- Neural or peripheral stimulator;
- Intra-orbital or encephalic metallic foreign bodies;
- Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago;
- Claustrophobia.
- Pregnant or breast-feeding women;
- Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
- Patients only
- Score \>2 on the modified Hachinski scale (Hachinski et al., 2012)
Who the study is looking for
- For all participants:
- French mother tongue
- right-handed
- with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)
- Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)
- Affiliated with a social security scheme
- Having received oral and written information about the protocol and having signed a consent form to participate in this research.
- DCS+ group:
- \- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014).
- Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA":
- \- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011))
- De novo" Parkinsonian patients, "MPdn":
- \- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))
- Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP":
- \- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012))
Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Rennes Coordinator of this site? Confirm its status | Rennes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.